Alfonso Soto

A Coruna, GA, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Multidisciplinary Delphi study on residual risk in patients with chronic kidney disease and type 2 diabetes mellitus.

Multidisciplinary Delphi study on residual risk in patients with chronic kidney disease and type 2 diabetes mellitus.

Journal: Nefrologia

Published: January 30, 2025

An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism.

An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism.

Journal: The Journal of clinical endocrinology and metabolism

Published: November 03, 2023

Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.

Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.

Journal: Frontiers in endocrinology

Published: June 14, 2023

Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study.

Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study.

Journal: Drugs in context

Published: November 17, 2021

Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.

Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.

Journal: Diabetes

Published: August 02, 2021

DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain.

DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain.

Journal: Journal of comparative effectiveness research

Published: May 06, 2021

Glycemic variability: prognostic impact on acute ischemic stroke and the impact of corrective treatment for hyperglycemia. The GLIAS-III translational study.

Glycemic variability: prognostic impact on acute ischemic stroke and the impact of corrective treatment for hyperglycemia. The GLIAS-III translational study.

Journal: Journal of translational medicine

Published: August 24, 2020

Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.

Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.

Journal: Diabetes, obesity & metabolism

Published: August 22, 2019

Erratum to: Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes.

Erratum to: Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: August 25, 2017

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes.

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: April 25, 2017

Glycemic control parameters in insulin-naïve patients with uncontrolled type 2 diabetes referred to endocrinologists, and degree of implementation of the national Spanish consensus for the management of hyperglycemia.

Glycemic control parameters in insulin-naïve patients with uncontrolled type 2 diabetes referred to endocrinologists, and degree of implementation of the national Spanish consensus for the management of hyperglycemia.

Journal: Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion

Published: March 11, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026